EURONEXT-PAR$DBVT
DBV Technologies · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
DBV Technologies reported financial results and business update for Q1 2024.
DBV Technologies reported a net loss of $27.3 million for Q1 2024, with cash and cash equivalents at $101.5 million. The company is progressing with its VITESSE Phase 3 clinical trial and appointed a new Chief Regulatory Officer.
- VITESSE enrollment is on track to screen the last patient by Q3 2024.
- Robert Pietrusko was appointed as Chief Regulatory Officer.
- Q1 2024 closed with a cash balance of $101.5 million.
- Net loss for the quarter was $27.3 million.
Headline financials
Revenue & EPS history
DBV Technologies · Revenue · Quarterly
$1.41M
Forward guidance
DBV Technologies expects its cash and cash equivalents to fund operations until December 31, 2024, and intends to seek additional capital for research and development efforts and potential launch of Viaskin Peanut.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.3%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+11.4%
Avg return
30 days after
47%
20 / 43 earnings
Positive
+21.6%
Q4 2018
Best reaction
-29.8%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | -4.3% | -83.9% | |
| Q3 2025 | -1.2% | -5.4% | -1.4% | |
| Q1 2025 | -4.4% | +4.2% | -7.3% | |
| Q4 2024 | +7.5% | +0.9% | -1.4% | |
| Q3 2024 | -2.5% | -11.3% | +380.9% | |
| Q1 2024 | +3.7% | -14.0% | -15.4% | |
| Q4 2023 | +1.2% | +1.1% | -9.6% | |
| Q3 2023 | -2.9% | -1.9% | -29.5% | |
| Q2 2023 | +1.9% | -2.5% | -3.2% | |
| Q1 2023 | +5.8% | +4.5% | +27.6% | |
| Q4 2022 | -0.7% | +4.1% | +16.6% | |
| Q3 2022 | +2.7% | +2.0% | -9.5% | |
| Q2 2022 | -5.5% | +3.5% | -21.2% | |
| Q1 2022 | -1.6% | +6.2% | +19.4% | |
| Q4 2021 | +3.1% | +0.8% | +22.3% | |
| Q3 2021 | -29.8% | -40.9% | -41.3% | |
| Q2 2021 | -4.4% | -8.1% | +7.7% | |
| Q1 2021 | -1.1% | +0.6% | +21.4% | |
| Q4 2020 | -0.4% | +2.9% | +86.2% | |
| Q3 2020 | +0.0% | -3.5% | -16.4% | |
| Q2 2020 | -3.0% | -3.5% | -16.8% | |
| Q1 2020 | -7.7% | -7.7% | +53.6% | |
| Q4 2019 | -1.2% | +3.6% | -11.7% | |
| Q3 2019 | -0.4% | +4.0% | -13.7% | |
| Q2 2019 | +5.5% | +26.5% | +17.2% | |
| Q1 2019 | -1.7% | +14.3% | +26.5% | |
| Q4 2018 | +21.6% | +34.8% | +16.3% | |
| Q3 2018 | -2.7% | -14.8% | -18.9% | |
| Q2 2018 | -1.9% | -0.1% | -8.2% | |
| Q1 2018 | -1.3% | +3.7% | -4.9% | |
| Q4 2017 | +3.5% | +7.8% | -4.7% | |
| Q3 2017 | +5.5% | -3.4% | +17.2% | |
| Q2 2017 | +1.4% | +1.3% | +25.0% | |
| Q1 2017 | -0.3% | -1.7% | +1.3% | |
| Q4 2016 | -1.1% | -0.4% | -1.0% | |
| Q3 2016 | +1.1% | +1.9% | -2.7% | |
| Q2 2016 | +3.5% | +0.6% | +6.8% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | +3.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro